Fiche traitement
Clopidogrel
Yonsei University • Accident vasculaire cérébral, Maladie coronarienne
Suivi actif
Phase 4
Résumé
Clopidogrel est développé par Yonsei University. Le traitement est actuellement en Phase 4. Il est associé à Accident vasculaire cérébral, Maladie coronarienne. Son objectif thérapeutique principal est Traitement symptomatique. Le statut actuel est : suivi actif.
À vérifier
Traitement symptomatique
Phase 4
Yonsei University
South Korea
Coronary artery disease occurs when the blood vessels supplying the heart become narrowed or blocked. Percutaneous coronary intervention (PCI) is a procedure used to restore blood flow to the heart, often by inserting a stent. After PCI, patients are commonly treated with dual antiplatelet therapy, which usually includes aspirin and a second medicine, such as clopidogrel, to reduce the risk of blood clots.
Clopidogrel must be converted by the body into its active form before it can work effectively. An enzyme called CYP2C19 plays an important role in this process. Genetic differences in the CYP2C19 gene can affect how well clopidogrel is activated. Some genetic variations, including CYP2C192 and CYP2C193, are associated with reduced enzyme activity, while CYP2C19\*17 is associated with increased enzyme activity. These differences may influence a patient's response to clopidogrel and could be related to cardiovascular events or bleeding after PCI.
There is limited information about the frequency of these genetic variations and their relationship with clinical outcomes among Egyptian patients receiving clopidogrel after PCI.
The purpose of this study is to determine the prevalence of CYP2C192, CYP2C193, and CYP2C19\*17 genetic variations in Egyptian patients undergoing PCI and receiving clopidogrel. The study will also examine the distribution of CYP2C19 genotypes and predicted metabolizer groups, their relationship with patient characteristics, and their potential association with cardiovascular events, bleeding, and hospitalizations after PCI.
Approximately 1,000 adult Egyptian patients will be recruited from multiple cardiac catheterization centers across Egypt. Information about participants' demographic characteristics, medical history, cardiovascular condition, and medications will be collected. A small blood sample (approximately 3 mL) will be obtained for DNA extraction and genetic testing using a laboratory method called TaqMan real-time polymerase chain reaction (PCR).
Participants' clinical outcomes will be assessed according to the study protocol, including cardiovascular events, heart attack, stent thrombosis, repeat coronary procedures, stroke, bleeding, and cardiovascular-related hospitalizations.
This is a prospective observational study. Participants will receive their clinical care according to the decisions of their treating healthcare professionals. The study will observe the relationship between genetic variations and clinical outcomes; it will not assign treatments based on genetic results.
The findings may improve understanding of CYP2C19 genetic variation in the Egyptian population and provide evidence to support future research on personalized antiplatelet treatment after PCI.
2026-10-12
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 4
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Traitement symptomatique
Confiance automatique : 66%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : symptom → Traitement symptomatique
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT07876336, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-10-12
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeStatut inconnu
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 4
Études associées1
Publications associées10
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
14 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2026-07-14 | PublicationPilot feasibility study of intraprocedural transcranial Doppler monitoring to assess Heal coating thrombogenicity in flow diversion. | Frontiers in neurology |
| 2026-07-23 | PublicationLow-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial. | JAMA cardiology |
| 2026-07-23 | PublicationAntithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches. | Cureus |
| 2026-08-01 | Début de l’étudeNCT07876336 | Registre d’essai clinique |
| 2026-08-16 | PublicationDifferent duration of dual antiplatelet therapy after endovascular treatment for unruptured intracranial aneurysms. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia |
| 2026-08-16 | PublicationImpact of dual antiplatelet therapy duration after percutaneous coronary intervention on outcomes in acute coronary syndrome patients with and without chronic kidney disease: a nationwide cohort study. | Renal failure |
| 2026-08-16 | PublicationThe influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. | Thrombosis research |
| 2026-08-16 | PublicationA comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. | American heart journal |
| 2026-08-16 | PublicationThe Development of Synthetic Routes Leading to Pharmaceuticals and the Key Intermediates Using Hydroxynitrile Lyase. | The Journal of organic chemistry |
| 2026-08-16 | PublicationHigh-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study. | Annals of medicine |
| 2026-08-16 | PublicationPrognostic implications of single antiplatelet therapy in individuals developing diabetic foot disease with concurrent peripheral arterial disease. | Annals of medicine |
| 2026-10-12 | Dernière mise à jour des donnéesClopidogrel | Biomedical Watch |
| 2026-10-18 | Création de l’enregistrementNCT07876336 | Registre d’essai clinique |
| 2027-06-30 | Fin de l’étude prévue / enregistréeNCT07876336 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT07876336 | Prevalence of CYP2C19 Genetic Polymorphisms Among Egyptian Patients Receiving Clopidogrel Following PCI | À vérifier | ENROLLING_BY_INVITATION | Egypt | October 6 University |
Publications liées
10 publication(s)Publications liées
10 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Different duration of dual antiplatelet therapy after endovascular treatment for unruptured intracranial aneurysms. Voir source | 42241917 | 10.1016/j.jocn.2026.112124 | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia | |
| Impact of dual antiplatelet therapy duration after percutaneous coronary intervention on outcomes in acute coronary syndrome patients with and without chronic kidney disease: a nationwide cohort study. Voir source | 42443728 | 10.1080/0886022X.2026.2697379 | Renal failure | |
| The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. Voir source | 25022828 | 10.1016/j.thromres.2014.05.019 | Thrombosis research | |
| A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. Voir source | 27823681 | 10.1016/j.ahj.2016.08.010 | American heart journal | |
| The Development of Synthetic Routes Leading to Pharmaceuticals and the Key Intermediates Using Hydroxynitrile Lyase. Voir source | 40400062 | 10.1021/acs.joc.5c00427 | The Journal of organic chemistry | |
| High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study. Voir source | 42311091 | 10.1080/07853890.2026.2682581 | Annals of medicine | |
| Prognostic implications of single antiplatelet therapy in individuals developing diabetic foot disease with concurrent peripheral arterial disease. Voir source | 41981998 | 10.1080/07853890.2026.2653300 | Annals of medicine | |
| Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial. Voir source | 41739450 | 10.1001/jamacardio.2026.0026 | JAMA cardiology | |
| Antithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches. Voir source | 42465709 | 10.7759/cureus.112751 | Cureus | |
| Pilot feasibility study of intraprocedural transcranial Doppler monitoring to assess Heal coating thrombogenicity in flow diversion. Voir source | 42422222 | 10.3389/fneur.2026.1831348 | Frontiers in neurology |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-10-12
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.